BioSpace News Archive

Pharmaceutical industry leader to join as the Company prepares for the Phase II clinical trial with merimepodib, an orally administered broad-spectrum anti-viral for COVID-19

oday Medicx Media Solutions (https://medicxmedia.com/), the leading analytics driven healthcare marketing solutions company, announced its upgraded capabilities to target healthcare practitioners (HCPs) at home or at work.

Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences Company, with proprietary CBD & CBG infused chewing gums and edibles product(s) as well as two ongoing Biotechnology initiatives, today showcased its Final blister pack design for its Black Cur

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company is pleased to announce that it will be featured on an upcoming BioPub webcast hosted by Dr. KSS on Monday June 1, 2020 at Noon EDT. to discuss its planned Multinational Phase 2b/3 Ifenprodil COVID-19 Human Trial. The Company invites interested shareholders, investors, membe

ViaCyte, Inc. , a privately held regenerative medicine company, announced today that ViaCyte’s President and CEO Paul Laikind , Ph.D. is scheduled to present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 10 a.m. Eastern Time in Track 9. The company recently announced a $27 million financing to advance

Bird Rock Bio, Inc., a clinical stage biopharmaceutical company, announced today that the Company has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a phase 2 clinical study of nimacimab, also known as RYI-018, in patients with one of the following renal dis

- New Phase 2 Study to Be Conducted in Collaboration with NIH Under a $2.7 Million Grant - - Management to Host Investor Conference Call and Webcast Today at 11:00 AM ET -

DURECT Corporation announced that James E. Brown, President and CEO, will be presenting at the Jefferies 2020 Virtual Health Care Conference, Wednesday, June 3, 2020 at 10:00 a.m. EDT / 7:00 a.m. PDT.

Guided Therapeutics and Chinese Partner Shandong Yaohua Medical Instrument Corporation Complete Key Step in Chinese FDA Approval Process

RefleXion Medical , a therapeutic oncology company pioneering biology-guided radiotherapy* ( BgRT ) for treating all stages of cancer, today announced a clinical collaboration with Merck (known as MSD outside the U.S. and Canada) to evaluate the safety and efficacy of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with BgRT in multiple late-stage cancers, including non-small cell lung cancer (NSCLC)